knowledge -WSS

knowledge

author：entertainment 2025-10-01 15:39:45 - browse：2756

Enticed by the immense market opened by GLP-1 weight loss drugs Wegovy and Zepbound, a handful of biotech companies are trying to develop next-generation, longer-lasting therapies based on a very different approach: RNA interference.

This Nobel Prize-winning science works by degrading the biological blueprints that RNA use to make proteins — without the genetic instructions, the troublesome proteins are never made and the gene is essentially muted.

If the companies succeed, it would be a significant shift in the obesity treatment revolution, away from weekly drugs targeting hormones to medications that could be given much less frequently — twice a year or even less — and pinpoint genetic contributors to weight.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Van's Gluten Free Original Waffles recalled for possible wheat allergen

WSS

When is a doctor not a doctor? Try when patients address women doctors

These geoengineering technologies could help combat the climate crisis, scientists say

4 killed, 7 hurt in mass shooting at July 4 block party in Louisiana; no arrests made

Flu, Covid vaccination rates decline, new survey data show

The United States is paying nearly triple for new Covid vaccines

2023 Nobel Prize in Medicine goes to Karikó and Weissman

leisure time

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

Walensky prepares to leave CDC — and Congress — behind

Connecting traumatic brain injury and domestic violence

Alkermes shareholders re

Experts study whether long Covid risk adds up with each reinfection

The cancer drug shortage isn’t new — and neither are the solutions

New oral drug delivery patch is modeled after octopus tentacles

BioMarin wins approval for gene therapy to treat hemophilia A

Ukraine, Russia accuse each other of planning to attack Europe's biggest nuclear plant

Psychedelics group wrestles with new pharma identity

New case study details death in closely watched Alzhiemer's trial

Wikipedia

Grail is spending more than ever lobbying Congress

Setback for rare diseases as Taysha Gene Therapies pulls back

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

CDC picks Alphabet's Verily for wasterwater surveillance contract

Why is France rioting? What to know about the fatal police shooting of Nahel M

Flu, Covid vaccination rates decline, new survey data show

entertainment

explore

leisure time

leisure time